Cargando…

Class I Histone Deacetylase Inhibitor Entinostat Suppresses Regulatory T Cells and Enhances Immunotherapies in Renal and Prostate Cancer Models

BACKGROUND: Immunosuppressive factors such as regulatory T cells (Tregs) limit the efficacy of immunotherapies. Histone deacetylase (HDAC) inhibitors have been reported to have antitumor activity in different malignancies and immunomodulatory effects. Herein, we report the Tregs-targeting and immune...

Descripción completa

Detalles Bibliográficos
Autores principales:	Shen, Li, Ciesielski, Michael, Ramakrishnan, Swathi, Miles, Kiersten M., Ellis, Leigh, Sotomayor, Paula, Shrikant, Protul, Fenstermaker, Robert, Pili, Roberto
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2012
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3267747/ https://www.ncbi.nlm.nih.gov/pubmed/22303460 http://dx.doi.org/10.1371/journal.pone.0030815

Ejemplares similares

Class I histone deacetylase inhibition is a novel mechanism to target regulatory T cells in immunotherapy
por: Shen, Li, et al.
Publicado: (2012)

Histone deacetylase inhibition by Entinostat for the prevention of electrical and structural remodeling in heart failure
por: Freundt, Johanna K., et al.
Publicado: (2019)

Phase I study of the histone deacetylase inhibitor entinostat in combination with 13-cis retinoic acid in patients with solid tumours
por: Pili, R, et al.
Publicado: (2012)

Entinostat, a histone deacetylase inhibitor, increases the population of IL-10(+) regulatory B cells to suppress contact hypersensitivity
por: Min, Keun Young, et al.
Publicado: (2021)

A ‘click’ chemistry approach to novel entinostat (MS-275) based class I histone deacetylase proteolysis targeting chimeras
por: Cross, Jasmine M., et al.
Publicado: (2022)

The histone deacetylase inhibiting drug Entinostat induces lipid accumulation in differentiated HepaRG cells
por: Nunn, Abigail D. G., et al.
Publicado: (2016)

Histone Deacetylase Inhibitors: Advancing Therapeutic Strategies in Hematological and Solid Malignancies
por: Ellis, Leigh, et al.
Publicado: (2010)

Erratum: The histone deacetylase inhibiting drug Entinostat induces lipid accumulation in differentiated HepaRG cells
por: Nunn, Abigail D. G., et al.
Publicado: (2016)

Identification of Jun loss promotes resistance to histone deacetylase inhibitor entinostat through Myc signaling in luminal breast cancer
por: Tanioka, Maki, et al.
Publicado: (2018)

A distal regulatory region of a class I human histone deacetylase
por: Werbeck, Nicolas D., et al.
Publicado: (2020)

Concurrent HDAC and mTORC1 Inhibition Attenuate Androgen Receptor and Hypoxia Signaling Associated with Alterations in MicroRNA Expression
por: Ellis, Leigh, et al.
Publicado: (2011)

HDAC 1 and 6 modulate cell invasion and migration in clear cell renal cell carcinoma
por: Ramakrishnan, Swathi, et al.
Publicado: (2016)

Phase I Study and Pilot Efficacy Analysis of Entinostat, a Novel Histone Deacetylase Inhibitor, in Chinese Postmenopausal Women with Hormone Receptor-Positive Metastatic Breast Cancer
por: Wang, Jiani, et al.
Publicado: (2021)

Histone Deacetylases and Their Regulatory MicroRNAs in Hepatocarcinogenesis
por: Kim, Hyung Seok, et al.
Publicado: (2015)

Entinostat, a class I selective histone deacetylase inhibitor, plus exemestane for Chinese patients with hormone receptor-positive advanced breast cancer: A multicenter, randomized, double-blind, placebo-controlled, phase 3 trial
por: Xu, Binghe, et al.
Publicado: (2023)

Revisiting entinostat as an immune-potentiating adjuvant
por: McCaw, Tyler R., et al.
Publicado: (2018)

Preclinical rationale for entinostat in embryonal rhabdomyosarcoma
por: Bharathy, Narendra, et al.
Publicado: (2019)

Inhibition of Hsp90 Augments Docetaxel Therapy in Castrate Resistant Prostate Cancer
por: Ku, ShengYu, et al.
Publicado: (2014)

Class I histone deacetylases (HDAC1–3) are histone lysine delactylases
por: Moreno-Yruela, Carlos, et al.
Publicado: (2022)

Histone Deacetylases and Histone Deacetylase Inhibitors in Neuroblastoma
por: Phimmachanh, Monica, et al.
Publicado: (2020)

Transcription Regulation by Class III Histone Deacetylases (HDACs)—Sirtuins
por: Dai, Yan, et al.
Publicado: (2008)

Eloquent silence: developmental functions of Class I histone deacetylases
por: Cunliffe, Vincent T
Publicado: (2008)

Class IIa Histone Deacetylases Are Conserved Regulators of Circadian Function
por: Fogg, Paul C. M., et al.
Publicado: (2014)

A Class 1 Histone Deacetylase with Potential as an Antifungal Target
por: Bauer, Ingo, et al.
Publicado: (2016)

The class II histone deacetylases as therapeutic targets for Parkinson’s disease
por: Mazzocchi, Martina, et al.
Publicado: (2020)

Targeting Class I Histone Deacetylases in Human Uterine Leiomyosarcoma
por: Yang, Qiwei, et al.
Publicado: (2022)

The role of class IIa histone deacetylases in regulating endothelial function
por: Shen, Zexu, et al.
Publicado: (2023)

Medicinal chemistry advances in targeting class I histone deacetylases
por: Abdallah, Diaaeldin I., et al.
Publicado: (2023)

Class I histone deacetylase complex: Structure and functional correlates
por: Wang, Xiao, et al.
Publicado: (2023)

Targeting SALL4 by entinostat in lung cancer
por: Yong, Kol Jia, et al.
Publicado: (2016)

Entinostat-Bortezomib Hybrids against Multiple Myeloma
por: Ferro, Angelica, et al.
Publicado: (2023)

Class I HDAC inhibitor entinostat synergizes with PLK1 inhibitors in MYC-amplified medulloblastoma cells
por: Valinciute, Gintvile, et al.
Publicado: (2023)

Histone deacetylase inhibition leads to regulatory histone mark alterations and impairs meiosis in oocytes
por: Legoff, Louis, et al.
Publicado: (2021)

Combinatorial antitumor effect of HDACs and the PI3K-Akt-mTOR pathway inhibition in a Pten deficient model of prostate cancer
por: Ellis, Leigh, et al.
Publicado: (2013)

Roles and Targets of Class I and IIa Histone Deacetylases in Cardiac Hypertrophy
por: Kee, Hae Jin, et al.
Publicado: (2011)

Electrocardiographic effects of class 1 selective histone deacetylase inhibitor romidepsin
por: Sager, Philip T, et al.
Publicado: (2015)

Subcellular Localization of Class I Histone Deacetylases in the Developing Xenopus tectum
por: Guo, Xia, et al.
Publicado: (2016)

Use of class I histone deacetylase inhibitor romidepsin in combination regimens
por: Petrich, Adam, et al.
Publicado: (2016)

Structure-Based Inhibitor Discovery of Class I Histone Deacetylases (HDACs)
por: Luo, Yuxiang, et al.
Publicado: (2020)

Overview of Histone Deacetylase Inhibitors in Haematological Malignancies
por: Bishton, Mark J., et al.
Publicado: (2010)

Cannot write session to /tmp/vufind_sessions/sess_332m1l57ciskk2gruiulee7poo